Corpus ID: 45766759

GPI-15715 Guilford.

@article{Krasowski2005GPI15715G,
  title={GPI-15715 Guilford.},
  author={M. D. Krasowski},
  journal={Current opinion in investigational drugs},
  year={2005},
  volume={6 1},
  pages={
          90-8
        }
}
  • M. D. Krasowski
  • Published 2005
  • Medicine
  • Current opinion in investigational drugs
  • GPI-15715 (PQ-1002, Aquavan), a water-soluble prodrug of propofol, is being developed by Guilford, under license from ProQuest, as a potential anesthetic agent. In May 2004, Guilford initiated phase III trials in the US to evaluate the sedative effects of this prodrug in several patient populations. 
    6 Citations

    Topics from this paper

    Drug development in anaesthesia: industrial perspective
    • 11
    Fospropofol, a new sedative anesthetic, and its utility in the perioperative period.
    • 11
    • PDF
    Perspectives on the Role of Fospropofol in the Monitored Anesthesia Care Setting
    • 12
    • PDF
    The discovery of new anesthetics by targeting GABAA receptors
    • 9